Generalized Myasthenia Gravis Clinical Trial
— ADAPT SERONOfficial title:
A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod IV in Adult Participants With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
The primary purpose of this study is to measure the efficacy and safety of efgartigimod intravenously (IV) compared to placebo in participants with Acetylcholine Receptor Binding Antibody (AChR-Ab) seronegative Generalized Myasthenia Gravis (gMG). Other objectives are to assess long-term efficacy, safety, and tolerability of efgartigimod. Study will consist of: - Screening - Part A: participants will be randomized to receive either efgartigimod IV or placebo - Part B: participants completing part A will receive open-label efgartigimod IV
Status | Recruiting |
Enrollment | 110 |
Est. completion date | July 23, 2027 |
Est. primary completion date | July 25, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - The participant is at least the local legal age of consent for clinical studies when signing the ICF. - The participant is capable of providing signed informed consent and following with protocol requirements. - The participant agrees to use contraceptive measures consistent with local regulations and the women of child-bearing potential (WOCBP) must have a negative serum pregnancy test result at screening and a negative urine pregnancy test result at baseline before receiving the study drug. - The participant has no known weakness in infancy and later develop fatigable weakness after aged 16 years and diagnosed with acquired gMG of both of the following: 1. History of abnormal neuromuscular transmission demonstrated by single fiber electromyography or repetitive nerve stimulation (RNS) or is anti-muscle-specific kinase antibodies (MuSK-Ab) seropositive 2. Either a history of positive edrophonium chloride test OR a demonstrated improvement in MG signs with treatments such as oral acetylcholinesterase (AChE) inhibitors, plasma exchange (PLEX), immunoabsorption, or intravenous immunoglobulin (IVIg)/ subcutaneous immunoglobulin (SCIg) treatment Exclusion Criteria: - Known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of gMG or puts the participant at undue risk - History of malignancy, cancer, unless considered cured by adequate treatment with no evidence of recurrence for =3 years. Adequately treated participants with the following cancers can be included at any time: Basal cell or squamous cell skin cancer, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, Incidental histological findings of prostate cancer - Clinically significant active infection that is not sufficiently resolved in the investigator's opinion or positive serum test at screening for active infection with any of the following: Hepatitis B virus (HBV), Hepatitis C virus (HCV), HIV - Current participation in another interventional clinical study or previous participation in an efgartigimod clinical study and received at least 1 dose of the study drug - Known hypersensitivity to study drug or one of its excipients (inactive ingredients) - History of or current alcohol, drug, or medication abuse as assessed by the investigator - Pregnant or lactating state or intention to become pregnant during the study - Live or live-attenuated vaccine received <4 weeks before screening - Worsening muscle weakness secondary to concurrent infections or medications - Received a thymectomy less than 3 months before screening or thymectomy is planned during the study - Use of some medications before screening (more information is found in the protocol). The complete list of exclusion criteria can be found in the protocol. |
Country | Name | City | State |
---|---|---|---|
United States | First Choice Neurology Boca Raton | Boca Raton | Florida |
Lead Sponsor | Collaborator |
---|---|
argenx |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Myasthenia Gravis Activities of Daily Living (MG-ADL) total score change from baseline | Minimum value: 0 (normal symptoms); Maximum value: 24 (most severe symptoms) | Up to 29 days during part A | |
Secondary | Quantitative myasthenia gravis (QMG) total score change from baseline | Minimum value: 0 (no disease severity); Maximum value: 39 (highest disease severity) | Up to 29 days during part A | |
Secondary | Proportion of participants who are both MG-ADL and QMG responders | Up to 8 weeks during part A |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05514873 -
An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
|
Phase 3 | |
Completed |
NCT04124965 -
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
|
Phase 3 | |
Recruiting |
NCT04833894 -
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
|
Phase 2/Phase 3 | |
Recruiting |
NCT04963270 -
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
|
Phase 3 | |
Active, not recruiting |
NCT02950155 -
A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis
|
Phase 3 | |
Completed |
NCT03315130 -
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
|
Phase 2 | |
Recruiting |
NCT05556096 -
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
|
Phase 3 | |
Not yet recruiting |
NCT06392386 -
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
|
Phase 3 | |
Not yet recruiting |
NCT06149559 -
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
|
Phase 2/Phase 3 | |
Completed |
NCT03920293 -
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
|
Phase 3 | |
Not yet recruiting |
NCT06193889 -
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis
|
Phase 2 | |
Completed |
NCT03770403 -
A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.
|
Phase 3 | |
Completed |
NCT03971422 -
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
|
Phase 3 | |
Recruiting |
NCT05403541 -
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
|
Phase 3 | |
Recruiting |
NCT05644561 -
Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
|
Phase 3 | |
Recruiting |
NCT06055959 -
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
|
Phase 2/Phase 3 | |
Completed |
NCT00515450 -
Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis
|
Phase 3 | |
Recruiting |
NCT06064695 -
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis
|
N/A | |
Withdrawn |
NCT04982289 -
Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis
|
Phase 2 | |
Completed |
NCT04735432 -
Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis
|
Phase 3 |